Gestational diabetes (GDM) is a common complication of pregnancy with significant consequences. Early identification and lifestyle intervention can prevent GDM, but the best early screening test is unknown. Our primary aim is to validate our first trimester screening test for GDM in a large multi-ethnic cohort to accurately predict high-risk women and intervene early, preventing GDM onset and improving pregnancy outcomes, including long-term risk of obesity in the offspring.
Analysis Of Effect Of Different Treatment Targets On Maternal And Child Health Outcomes In Gestational Diabetes Mellitus (GDM), Review Of Specific Treatments And Development Of Clinical And Biochemical Predictors.
Funder
National Health and Medical Research Council
Funding Amount
$122,686.00
Summary
This research aims to analyse newly proposed treatment targets for Gestational Diabetes Mellitus (GDM) and the effect this will have on maternal and child health outcomes, via comparison of data from two large Australian health services using the traditional and newly proposed critiera. The research will also investigate current effective interventions for GDM, including the impact of early antenatal lifestyle interventions, and formulation of a clinical and biochemical risk prediction model.
Gestational diabetes is an important medical condition. We plan to investigate two subgroups of women with gestational diabetes. Firstly, women who have diabetes antibodies in pregnancy. Secondly, women who have a mild form of diabetes caused by a single gene mutation, who may be first identified during pregnancy. Correct identification of these subgroups of women is important for immediate and long-term management of both the mother and her fetus.
The Treatment Of BOoking Gestational Diabetes Mellitus Study: The TOBOGM Study
Funder
National Health and Medical Research Council
Funding Amount
$2,197,280.00
Summary
Gestational diabetes mellitus (GDM) related pregnancy complications are reduced with treatment from 24-28 weeks pregnant. Many women are diagnosed/treated earlier without evidence of benefit and possible risk of harm. In TOBOGM women under 20 weeks pregnant with mildly raised blood glucose will be allocated by chance to either immediate treatment, or awaiting a repeat diabetes test at 24-28 weeks pregnant to decide treatment. Harmful and beneficial effects on mother and baby will be compared.
NTDIP: Northern Territory Diabetes In Pregnancy Project
Funder
National Health and Medical Research Council
Funding Amount
$1,572,386.00
Summary
Diabetes in pregnancy provides exposure to high sugar levels before birth which can result in the child developing obesity, diabetes and cardiovascular disease later in life. This study aims to optimise the diagnosis and management of diabetes in pregnancy in the Northern Territory, thereby targeting the causes of chronic diseases from as early as possible in the life course, which we believe is a key step in closing the gap in life expectancy between Indigenous and non-Indigenous Australians.
Improving The Management Of Diabetes In Pregnancy In Remote Australia
Funder
National Health and Medical Research Council
Funding Amount
$2,117,449.00
Summary
This study aims to optimise the management of diabetes in pregnancy (both gestational diabetes and pre-existing type 2 diabetes) and post-partum follow-up of these high risk women in order to reduce the risk of future chronic disease among women and their children. The proposal involves scale-up of successful initiatives that we have developed as part of the NT DIP Partnership, scale-up within the Northern Territory (NT) and to Far North Queensland (FNQ).
Pregnancy And Neonatal Diabetes Outcomes In Remote Australia (PANDORA) Cohort
Funder
National Health and Medical Research Council
Funding Amount
$2,395,410.00
Summary
The PANDORA study is a longitudinal birth cohort study recruited from a clinical register of Northern Territory women with diabetes in pregnancy (DIP). We will also recruit a comparator group of mothers without DIP and babies. Follow-up of mothers and infants to 3 years post-delivery will be from medical records, questionnaires and clinical assessment. Rates of progression to type 2 diabetes will be assessed among mothers, and growth, feeding patterns and diabetes risk markers among infants.
Outcomes In Early Diagnosis And Intervention For Gestational Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$162,876.00
Summary
Gestational diabetes mellitus (GDM) is a common complication of pregnancy with significant maternal and fetal consequences. The benefits of screening and treatment for GDM after 24 weeks’ gestation are well known, however there is little evidence for early screening and intervention for women with high risk for GDM. The primary aim of this study is to determine whether early diagnosis and intervention improves pregnancy outcomes in GDM, specifically fetal overgrowth.
Fragility Fractures: The Neglected Role Of Cortical Porosity
Funder
National Health and Medical Research Council
Funding Amount
$865,474.00
Summary
We just discovered that bone lost with age occurs mostly from pores within the cortex (outer shell) of the bone; These pores become larger (porosity) making bones fragile. This process is poorly detected by bone density (currently used tool) so that most people with weak bones are missed. To address this issue, we have for the first time, develop a technology to accurately quantify porosity in living peoples. With teams around the world, we aim here to fill this gap in the diagnosis.
Interaction Between PTH And Y2 Bone Anabolic Pathways
Funder
National Health and Medical Research Council
Funding Amount
$731,311.00
Summary
Osteoporosis is a costly condition that affects more than 150 million people worldwide and fills more hospital beds than any other disease*. People who have osteoporotic fractures experience a diminished quality of life and a reduced life expectancy. Although there are currently a number of therapies in use to reduce further loss of bone in osteoporotic patients, there is only one to replace lost bone, parathyroid hormone. For clinical and economic reasons, there is a need for additional bone-bu ....Osteoporosis is a costly condition that affects more than 150 million people worldwide and fills more hospital beds than any other disease*. People who have osteoporotic fractures experience a diminished quality of life and a reduced life expectancy. Although there are currently a number of therapies in use to reduce further loss of bone in osteoporotic patients, there is only one to replace lost bone, parathyroid hormone. For clinical and economic reasons, there is a need for additional bone-building therapies. Like all tissues, the nervous system affects skeletal function. We recently discovered a powerful control pathway by which the nervous system regulates bone formation. This project will test whether altering the function of this neural pathway can increase bone formation and whether it can work together with parathyroid hormone therapy to produce an enhanced bone formation response greater than either therapy alone. This research is important because of the need for new osteoporosis therapies to repair weakened bones. The knowledge gained from this study has the potential to provide a very important and useful contribution to skeletal health and thus aged health worldwide. *The Burden of Brittle Bones: Costing Osteoporosis in Australia. A report prepared by Access Economics Pty. Ltd. September 2001Read moreRead less